Given this important point and the known importance of SMAD1/5 activity as a driver of pathogenic cardiac hypertrophy, it may be possible that the observation by Jaffré et al. with BIX02189 could be due to the inhibition of the TGFβR/SMAD pathway8. This evidence concerns the gene SMAD1 and cardiac hypertrophy.